Pharmacy World and Science

, Volume 23, Issue 2, pp 76–81 | Cite as

Evidence based information on drug use during pregnancy: a survey of community pharmacists in three countries

  • Dorothy A. Lyszkiewicz
  • Gideon Koren
  • Adrienne Einarson
  • Suzanne Gerichhausen
  • Ingunn Björnsdóttir
  • Thomas R. Einarson


Objective: To evaluate whether community pharmacists provide evidence‐based information to women inquiring about specific drug use during pregnancy.Design: A trained female student posing as a surrogate shopper requested information about the relative safety/risks of medications during pregnancy in two scenarios. Forty randomly selected pharmacies were surveyed in the Netherlands, Canada and Iceland, and pharmacists' recommendations were noted. Main outcome measures included the type of information that was provided, its presentation, and the source of information used. Results: A relatively small proportion of pharmacists surveyed, provided evidence‐based information regarding the drugs in question. Only 14% referred to current medical literature, while 60% consulted the product monograph. Over 90% of pharmacists referred the client to a physician. Conclusions: Community pharmacists do not disseminate evidence‐based recommendations when counseling women on drug use in pregnancy, and need further education on resources concerning drugs in pregnancy that are currently available.

Carbamazepine Counseling Fluoxetine Metronidazole Pharmacist Pregnancy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Preface. In: Koren G, Maternal-Fetal Toxicology: A Clinician's Guide. Marcel Dekker, Inc. 1994.Google Scholar
  2. 2.
    Einarson A, Bailey B, Jung G, Spizzirri D, Baillie M, Koren G. Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Ann All Asthma Immunol 1997;78:183-6.Google Scholar
  3. 3.
    Bond C, Bradley C. The interface between the community pharmacist and patients. BMJ 1996;312:758-60.Google Scholar
  4. 4.
    Bass M. The pharmacist as a provider of primary care. CMAJ 1975;112:60-4.Google Scholar
  5. 5.
    Pole M, Einarson A, Pairaudeau N, Einarson T, Koren G. Drug labeling and risk perceptions of teratogenicity: A survey of pregnant Canadian women and their health professionals. J Clin Pharmacol 2000;40:1-5.Google Scholar
  6. 6.
    Lamsam GD, Kropff MA. Community pharmacists assessments and recommendations for treatment in four case scenarios. Ann Pharmacother 1998;32:409-16.Google Scholar
  7. 7.
    Einarson A. Patient advice on drug use in pregnancy and lactation. Pharmacy Connection 1995;Jan/Feb:17-18.Google Scholar
  8. 8.
    Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S et al. Pregnancy outcome following first-trimester exposure to fluoxetine. JAMA 1993;269:2246-8.Google Scholar
  9. 9.
    Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester exposure on the newborn. Obstet Gynecol 1997;89:713-8.Google Scholar
  10. 10.
    Goldstein DJ. Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol 1995;6:417-20.Google Scholar
  11. 11.
    Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Koren G et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997;336:258-62.Google Scholar
  12. 12.
    Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychol Med 2000;1:89-94.Google Scholar
  13. 13.
    Rosabaum, Zajecka J. Clinical management of antidepressant discontinuation. J Clin Psychol 1997; 58 (Suppl) 7:37-40.Google Scholar
  14. 14.
    Einarson A, Koren G. Can we use metronidazole during pregnancy and breastfeeding? Putting an end to the controversy. Can Fam Physic 2000;46:1053-4.Google Scholar
  15. 15.
    Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. Baltimore: Williams and Wilkins, 1994.Google Scholar
  16. 16.
    Beard CM, Noller KL, O'Fallon WM, Kurland LT, Dockerty MB. Lack of evidence for cancer due to use of metronidazole. N Engl J Med 1979;301:519-22.Google Scholar
  17. 17.
    Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol 1993;82:348-52.Google Scholar
  18. 18.
    Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 1995;172(2 Pt 1):525-9.Google Scholar
  19. 19.
    Caro-Paton T, Carvajal A, Martin de Diego I, Alvarez Requejo A, Martin Amas LH, Rodriguez Pinilla E, et al. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 1997;44:179-82.Google Scholar
  20. 20.
    Smith J, Taddio A, Koren G. Chapter 8: Drugs of choice in pregnant women. In: Koren G, Maternal-Fetal Toxicology: A Clinician's Guide. Second edition. Marcel Dekker, Inc. New York.1994:124.Google Scholar
  21. 21.
    Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991;324:674-7.Google Scholar
  22. 22.
    Byrne B. Epilepsy and pregnancy. Ir Med J 1997;90(5):172-4.Google Scholar
  23. 23.
    Laurence KM, James N, Miller MH, Tennant GB, Campbell H. Double-blind randomized controlled trial of folate treatment before conception to prevent recurrence of neutral tube defects. Br Med J 1981;282:1509-11Google Scholar
  24. 24.
    MRC Vitamin Study Research Group. Prevention of neural tube defects: Results of the Medical Research Council vitamin study. Lancet 1991;338:131-7Google Scholar
  25. 25.
    Delgado-Escueta AV, Janz D. Consensus guidelines: Preconception counseling, management and care of the pregnant woman with epilepsy. Neurology 1992;42(Suppl 5):149-60Google Scholar
  26. 26.
    van der Pal-de Bruin KM, de Walle HE, Jeeninga W, de Rover C, Cornel MC, de Jong-van den Berg LT, Schouten J, Brand R, et al. The Dutch “Folic Acid Campaign”-have the goals been achieved? Paediatr Perinat Epidemiol 2000; 2:111-7.Google Scholar
  27. 27.
    Bonati M, Addis A. Informing women about they take during pregnancy: promoting consumers drug information as integral part of care. Pharm World Sci 1998;20:236-7.Google Scholar
  28. 28.
    Hassell K, Noyce PR, Rogers A, Harris J, Wilkinson J. A pathway to the GP: the pharamceutical “consultation” as a first port of call in primary health care. Fam Pract 1997;14:498-502.Google Scholar
  29. 29.
    Juergens JP, Basara LR. Patient information: Community pharmacy needs and perspectives. Top Hosp Pharm Manag 1994;14:47-57.Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Dorothy A. Lyszkiewicz
    • 1
  • Gideon Koren
    • 1
  • Adrienne Einarson
    • 1
  • Suzanne Gerichhausen
    • 2
  • Ingunn Björnsdóttir
    • 3
  • Thomas R. Einarson
    • 4
  1. 1.Motherisk Program, Division of Clinical PharmacologyHospital for Sick ChildrenTorontoCanada
  2. 2.Faculty of PharmacyUtrechtThe Netherlands
  3. 3.Pharmaceutical Society of IcelandUniversity of TorontoCanada
  4. 4.Faculty of PharmacyUniversity of Toronto, Faculty of Medicine, Department of Health AdministrationCanada

Personalised recommendations